Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. It may affect the peripheral joints, the spine and the entheses. Over the past several decades it revealed itself as a systemic disease as severe as Rheumatoid Arthritis (RA) though it is most of the times
seronegative for rheumatoid factor. PsA causes impressive inflammation, deformities and joint damage leading to impaired quality of life and function. It is associated with increased morbidity and mortality risk. We have better insight into the inflammatory and immunologic mechanism involved
in this condition, the inflammatory cells, cytokines, adhesion molecules which helped finding the targets for treatment. Over a decade ago with the discovery of the anti-tumor necrosis factor alpha (TNFα) inhibitors we finally found the treatment to reduce the progression of joint damage.
Starting this treatment early in the course of disease prevents the joint damage, improves the functional capacity and the survival of the patients with PsA. The biologic medications are effective in reducing dactylitis and enthesitis which are rarely improved by conventional treatments.
Current Rheumatology Reviews publishes frontier reviews on all the latest advances on rheumatology and its related areas e.g. pharmacology, pathogenesis, epidemiology, clinical care, and therapy. The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field.
The journal is essential reading for all researchers and clinicians in rheumatology.